Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study.

MLA

Fourati, Slim, et al. “Genotypic and Phenotypic Characterisation of Respiratory Syncytial Virus after Nirsevimab Breakthrough Infections: A Large, Multicentre, Observational, Real-World Study.” The Lancet. Infectious Diseases, Oct. 2024. EBSCOhost, https://doi.org/10.1016/S1473-3099(24)00570-X.

APA

Fourati, S., Reslan, A., Bourret, J., Casalegno, J.-S., Rahou, Y., Chollet, L., Pillet, S., Tremeaux, P., Dossou, N. C., Gault, E., Salmona, M., Imbert-Marcille, B.-M., Mirand, A., Larrat, S., Moisan, A., Marot, S., Schnuriger, A., Veyrenche, N., Engelmann, I., … Rameix-Welti, M.-A. (2024). Genotypic and phenotypic characterisation of respiratory syncytial virus after nirsevimab breakthrough infections: a large, multicentre, observational, real-world study. The Lancet. Infectious Diseases. https://doi.org/10.1016/S1473-3099(24)00570-X

Chicago

Fourati, Slim, Alawiya Reslan, Jérome Bourret, Jean-Sébastien Casalegno, Yannis Rahou, Lionel Chollet, Sylvie Pillet, et al. 2024. “Genotypic and Phenotypic Characterisation of Respiratory Syncytial Virus after Nirsevimab Breakthrough Infections: A Large, Multicentre, Observational, Real-World Study.” The Lancet. Infectious Diseases, October. doi:10.1016/S1473-3099(24)00570-X.